Differences in receipt of opioid agonist treatment and time to enter treatment for opioid use disorder among specialty addiction programs in the United States, 2014-17


Autoři: Justin C. Yang aff001;  Andres Roman-Urrestarazu aff001;  Carol Brayne aff001
Působiště autorů: Department of Public Health & Primary Care, Institute of Public Health, University of Cambridge, Cambridge, England, United Kingdom aff001;  Department and Epidemiology and Applied Clinical Research, Division of Psychiatry, Faculty of Brain Sciences, University College London, London, England, United Kingdom aff002;  Department of International Health, Care and Public Health Research Institute, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands aff003
Vyšlo v časopise: PLoS ONE 14(12)
Kategorie: Research Article
doi: 10.1371/journal.pone.0226349

Souhrn

Background

Access to adequate treatment for opioid use disorder (OUD) has been a high priority among American policymakers. Elucidation of the sociodemographic and institutional differences associated with the use, or lack thereof, of opioid agonist therapy (OAT) provides greater clarity on who receives OAT. Timely access to care is a further consideration and bears scrutiny as well.

Methods

We draw upon data from the Treatment Episode Data Set—Admissions (TEDS-A) to analyse the relationship between sociodemographic and institutional characteristics and the receipt of opioid agonist treatments and time waiting to enter treatment.

Results

Estimates from logistic regression models highlight certain groups which show lower odds of receipt of OAT, including those in precarious housing arrangements, those unemployed or not otherwise in the labor force, and those referred by drug abuse care providers, educational institutions, employers, and the criminal justice system. Groups which showed higher odds of waiting over a week to enter treatment included those who were separated, divorced, or widowed, those working part-time, and those referred by drug abuse care providers, employers, and the criminal justice system.

Conclusion

Given the efficacy of OAT and the adverse outcomes associated with long waiting times, coordinated effort is needed to understand why these differences persist and how they may be addressed through appropriate policy responses.

Klíčová slova:

Alcohols – Employment – Medicare – Native American people – Opioids – Outpatients – Socioeconomic aspects of health – Veteran care


Zdroje

1. Degenhardt L, Charlson F, Mathers B, Hall WD, Flaxman AD, Johns N, et al. The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study. Addiction. 2014;109(8):1320–33. Epub 2014/03/26. doi: 10.1111/add.12551 24661272.

2. Kolodny A, Courtwright DT, Hwang CS, Kreiner P, Eadie JL, Clark TW, et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annual review of public health. 2015;36:559–74. Epub 2015/01/13. doi: 10.1146/annurev-publhealth-031914-122957 25581144.

3. Yang JC, Roman-Urrestarazu A, Brayne C. Binge alcohol and substance use across birth cohorts and the global financial crisis in the United States. PLoS One. 2018;13(6):e0199741. Epub 2018/06/26. doi: 10.1371/journal.pone.0199741 29940033.

4. Armenian P, Vo KT, Barr-Walker J, Lynch KL. Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review. Neuropharmacology. 2018;134(Pt A):121–32. Epub 2017/10/19. doi: 10.1016/j.neuropharm.2017.10.016 29042317.

5. Rudd RA. Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. MMWR Morbidity and mortality weekly report. 2016;65.

6. Chen LY, Strain EC, Crum RM, Mojtabai R. Gender differences in substance abuse treatment and barriers to care among persons with substance use disorders with and without comorbid major depression. J Addict Med. 2013;7(5):325–34. Epub 2013/10/05. doi: 10.1097/ADM.0b013e31829b7afe 24091763.

7. Choi NG, DiNitto DM, Marti CN. Treatment use, perceived need, and barriers to seeking treatment for substance abuse and mental health problems among older adults compared to younger adults. Drug Alcohol Depend. 2014;145:113–20. Epub 2014/12/03. doi: 10.1016/j.drugalcdep.2014.10.004 25456572.

8. Blanco C, Iza M, Schwartz RP, Rafful C, Wang S, Olfson M. Probability and predictors of treatment-seeking for prescription opioid use disorders: a national study. Drug Alcohol Depend. 2013;131(1–2):143–8. Epub 2013/01/12. doi: 10.1016/j.drugalcdep.2012.12.013 23306097.

9. Krawczyk N, Feder KA, Fingerhood MI, Saloner B. Racial and ethnic differences in opioid agonist treatment for opioid use disorder in a U.S. national sample. Drug and Alcohol Dependence. 2017;178:512–8. https://doi.org/10.1016/j.drugalcdep.2017.06.009. 28719885

10. Peles E, Schreiber S, Adelson M. Opiate-Dependent Patients on a Waiting List for Methadone Maintenance Treatment Are at High Risk for Mortality Until Treatment Entry. 2013;7(3):177–82. doi: 10.1097/ADM.0b013e318287cfc9 23519049

11. Quinn PD, Hur K, Chang Z, Krebs EE, Bair MJ, Scott EL, et al. Incident and long-term opioid therapy among patients with psychiatric conditions and medications: a national study of commercial health care claims. Pain. 2017;158(1):140–8. Epub 2016/12/17. doi: 10.1097/j.pain.0000000000000730 27984526.

12. Short VL, Hand DJ, MacAfee L, Abatemarco DJ, Terplan M. Trends and disparities in receipt of pharmacotherapy among pregnant women in publically funded treatment programs for opioid use disorder in the United States. Journal of substance abuse treatment. 2018;89:67–74. Epub 2018/05/01. doi: 10.1016/j.jsat.2018.04.003 29706175.

13. Fullerton CA, Kim M, Thomas CP, Lyman DR, Montejano LB, Dougherty RH, et al. Medication-Assisted Treatment With Methadone: Assessing the Evidence. Psychiatric Services. 2014;65(2):146–57. doi: 10.1176/appi.ps.201300235 24248468

14. Thomas CP, Fullerton CA, Kim M, Montejano L, Lyman DR, Dougherty RH, et al. Medication-Assisted Treatment With Buprenorphine: Assessing the Evidence. Psychiatric Services. 2014;65(2):158–70. doi: 10.1176/appi.ps.201300256 24247147

15. Jaffe JH, O’Keeffe C. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend. 2003;70(2 Suppl):S3–11. Epub 2003/05/10. doi: 10.1016/s0376-8716(03)00055-3 12738346.

16. Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment. Am J Public Health. 2015;105(8):e55–63. Epub 2015/06/13. doi: 10.2105/AJPH.2015.302664 26066931.

17. Lofwall MR, Havens JR. Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine. Drug Alcohol Depend. 2012;126(3):379–83. Epub 2012/06/19. doi: 10.1016/j.drugalcdep.2012.05.025 22704124.

18. Gryczynski J, Schwartz RP, Salkever DS, Mitchell SG, Jaffe JH. Patterns in admission delays to outpatient methadone treatment in the United States. Journal of substance abuse treatment. 2011;41(4):431–9. https://doi.org/10.1016/j.jsat.2011.06.005. 21821378

19. Substance Abuse Mental Health Services Administration CfBHSQ. Treatment Episode Data Set (TEDS): 2004–2014. National Admissions to Substance Abuse Treatment Services. No BHSIS Series S-84, HHS Publication No SMA 16–4986. 2016.

20. Krawczyk N, Picher CE, Feder KA, Saloner B. Only One In Twenty Justice-Referred Adults In Specialty Treatment For Opioid Use Receive Methadone Or Buprenorphine. Health Affairs. 2017;36(12):2046–53. doi: 10.1377/hlthaff.2017.0890 29200340

21. Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. Journal of addiction medicine. 2015;9(5):358–67. doi: 10.1097/ADM.0000000000000166 26406300.

22. Bachhuber MA, Mehta PK, Faherty LJ, Saloner B. Medicaid Coverage of Methadone Maintenance and the Use of Opioid Agonist Therapy Among Pregnant Women in Specialty Treatment. Medical care. 2017;55(12):985–90. Epub 2017/11/15. doi: 10.1097/MLR.0000000000000803 29135769.

23. Chhatre S, Cook R, Mallik E, Jayadevappa R. Trends in substance use admissions among older adults. BMC health services research. 2017;17(1):584. Epub 2017/08/24. doi: 10.1186/s12913-017-2538-z 28830504.

24. Huhn AS, Strain EC, Tompkins DA, Dunn KE. A hidden aspect of the U.S. opioid crisis: Rise in first-time treatment admissions for older adults with opioid use disorder. Drug Alcohol Depend. 2018;193:142–7. Epub 2018/11/02. doi: 10.1016/j.drugalcdep.2018.10.002 30384321.

25. Krawczyk N, Picher CE, Feder KA, Saloner B. Only One In Twenty Justice-Referred Adults In Specialty Treatment For Opioid Use Receive Methadone Or Buprenorphine. Health Aff (Millwood). 2017;36(12):2046–53. Epub 2017/12/05. doi: 10.1377/hlthaff.2017.0890 29200340.

26. Peindl KS, Mannelli P, Wu LT, Patkar AA. Trends in nonheroin opioid abuse admissions: 1992–2004. Journal of opioid management. 2007;3(4):215–23. Epub 2007/10/26. doi: 10.5055/jom.2007.0007 17957981

27. Rivers PA, Dobalian A, Oyana TJ, Bae S. Socioeconomic determinants of planned methadone treatment. American journal of health behavior. 2006;30(5):451–9. Epub 2006/08/09. 16893307.

28. Uchtenhagen A, Ladjevic T, Rehm JJWGPAPOD. WHO guidelines for psychosocially assisted pharmacological treatment of persons dependent on opioids. 2007.

29. Stata Statistical Software. Release 14 [computer program]. 2013.

30. Carise D, McLellan AT, Gifford LS, Kleber HD. Developing a National Addiction Treatment Information System: An Introduction to the Drug Evaluation Network System. Journal of substance abuse treatment. 1999;17(1):67–77. https://doi.org/10.1016/S0740-5472(98)00047-6.

31. Dick AW, Pacula RL, Gordon AJ, Sorbero M, Burns RM, Leslie D, et al. Growth In Buprenorphine Waivers For Physicians Increased Potential Access To Opioid Agonist Treatment, 2002–11. Health Affairs. 2015;34(6):1028–34. doi: 10.1377/hlthaff.2014.1205 26056209

32. Stein BD, Gordon AJ, Dick AW, Burns RM, Pacula RL, Farmer CM, et al. Supply of buprenorphine waivered physicians: The influence of state policies. Journal of substance abuse treatment. 2015;48(1):104–11. https://doi.org/10.1016/j.jsat.2014.07.010. 25218919

33. Stein BD, Pacula RL, Gordon AJ, Burns RM, Leslie DL, Sorbero MJ, et al. Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties. The Milbank Quarterly. 2015;93(3):561–83. doi: 10.1111/1468-0009.12137 26350930

34. King NB, Fraser V, Boikos C, Richardson R, Harper S. Determinants of increased opioid-related mortality in the United States and Canada, 1990–2013: a systematic review. American journal of public health. 2014;104(8):e32–e42. doi: 10.2105/AJPH.2014.301966 24922138

35. Santoro TN, Santoro JD. Racial Bias in the US Opioid Epidemic: A Review of the History of Systemic Bias and Implications for Care. Cureus. 2018;10(12):e3733. Epub 2019/02/26. doi: 10.7759/cureus.3733 30800543.

36. Perlman DC, Jordan AE. The Syndemic of Opioid Misuse, Overdose, HCV, and HIV: Structural-Level Causes and Interventions. Current HIV/AIDS reports. 2018;15(2):96–112. Epub 2018/02/21. doi: 10.1007/s11904-018-0390-3 29460225.

37. Hileman CO, McComsey GA. The Opioid Epidemic: Impact on Inflammation and Cardiovascular Disease Risk in HIV. Current HIV/AIDS reports. 2019;16(5):381–8. Epub 2019/09/02. doi: 10.1007/s11904-019-00463-4 31473903.

38. Schwartz R, Sharma A, O’Grady K, Kelly S, Gryczynski J, Mitchell S. Pharmacotherapy for opioid dependence in jails and prisons: research review update and future directions. Substance Abuse and Rehabilitation. 2016:27. doi: 10.2147/sar.s81602 27217808

39. Joudrey PJ, Khan MR, Wang EA, Scheidell JD, Edelman EJ, McInnes DK, et al. A conceptual model for understanding post-release opioid-related overdose risk. Addiction Science & Clinical Practice. 2019;14(1). doi: 10.1186/s13722-019-0145-5 30982468

40. Kreek MJ, Reed B, Butelman ER. Current status of opioid addiction treatment and related preclinical research. Science Advances. 2019;5(10):eaax9140. doi: 10.1126/sciadv.aax9140 31616793

41. Bell J, Strang J. Medication Treatment of Opioid Use Disorder. Biol Psychiatry. 2019. Epub 2019/08/20. doi: 10.1016/j.biopsych.2019.06.020 31420089.


Článek vyšel v časopise

PLOS One


2019 Číslo 12